Design and rationale of the INSYTE study: a randomised, placebo controlled study to test the efficacy of a synbiotic on liver fat, disease biomarkers and intestinal …
E Scorletti, PR Afolabi, EA Miles, DE Smith… - Contemporary clinical …, 2018 - Elsevier
Background Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of fat-related
conditions ranging from simple fatty liver, to non-alcoholic steatohepatitis (NASH), fibrosis …
conditions ranging from simple fatty liver, to non-alcoholic steatohepatitis (NASH), fibrosis …
Design and rationale of the INSYTE study: A randomised, placebo controlled study to test the efficacy of a synbiotic on liver fat, disease biomarkers and intestinal …
E Scorletti, PR Afolabi, EA Miles, DE Smith… - 2018 - pubmed.ncbi.nlm.nih.gov
Background Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of fat-related
conditions ranging from simple fatty liver, to non-alcoholic steatohepatitis (NASH), fibrosis …
conditions ranging from simple fatty liver, to non-alcoholic steatohepatitis (NASH), fibrosis …
[PDF][PDF] Design and rationale of the INSYTE study: A randomised, placebo controlled study to test the efficacy of a synbiotic on liver fat, disease biomarkers and …
E Scorletti, PR Afolabi, EA Miles, DE Smith… - academia.edu
Southampton, UK; 2 National Institute for Health Research Southampton Biomedical
Research Centre University of Southampton and University Hospital Southampton National …
Research Centre University of Southampton and University Hospital Southampton National …
Design and rationale of the INSYTE study: a randomised, placebo controlled study to test the efficacy of a synbiotic on liver fat, disease biomarkers and intestinal …
E Scorletti, PR Afolabi, EA Miles… - Contemporary …, 2018 - eprints.soton.ac.uk
Background: Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of fat-related
conditions ranging from simple fatty liver, to non-alcoholic steatohepatitis (NASH), fibrosis …
conditions ranging from simple fatty liver, to non-alcoholic steatohepatitis (NASH), fibrosis …
Design and rationale of the INSYTE study: A randomised, placebo controlled study to test the efficacy of a synbiotic on liver fat, disease biomarkers and intestinal …
E Scorletti, PR Afolabi, EA Miles, DE Smith… - Contemporary …, 2018 - europepmc.org
Background Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of fat-related
conditions ranging from simple fatty liver, to non-alcoholic steatohepatitis (NASH), fibrosis …
conditions ranging from simple fatty liver, to non-alcoholic steatohepatitis (NASH), fibrosis …
Design and rationale of the INSYTE study: A randomised, placebo controlled study to test the efficacy of a synbiotic on liver fat, disease biomarkers and intestinal …
E Scorletti, PR Afolabi, EA Miles, DE Smith… - Contemporary …, 2018 - dial.uclouvain.be
(eng) BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of
fat-related conditions ranging from simple fatty liver, to non-alcoholic steatohepatitis (NASH) …
fat-related conditions ranging from simple fatty liver, to non-alcoholic steatohepatitis (NASH) …